CMD Dermatología common mistakes
CMD Dermatología · Understand the traps and how to avoid them.
Describing a lesion as 'eritematoso' or 'lesión' and stopping there, instead of committing to a primary lesion type (mácula, pápula, placa, vesícula, pústula, nódulo) plus distribution and configuration before generating a differential.
Candidates rush to a diagnosis name they recognize and skip the descriptive step, so they anchor on the wrong morphologic category and cannot recover when the stem describes something slightly different.
What to do instead
Before answering, write out in the margin: primary lesion, secondary changes, distribution (acral/flexural/photodistributed/dermatomal), configuration (anular, linear, reticular), and evolution. Only then name a diagnosis; if the stem's morphology contradicts your diagnosis, discard it.
Treating 'biopsia' as automatically indicated for every inflammatory eruption, or conversely never choosing it when the stem shows a treatment-refractory or atypical eruption, instead of weighing whether histology will change management.
Exam stems reward the 'do the gold standard test' reflex, but dermatology questions often test the opposite skill: recognizing when clinical diagnosis is sufficient and biopsy would be non-diagnostic or premature.
What to do instead
Ask whether the differential includes conditions with different management that cannot be separated clinically (e.g., psoriasis vs. nummular eczema vs. mycosis fungoides). If yes, biopsy; if the morphology is pathognomonic or the diagnosis is clinical by definition, do not.
Confusing the clinical phenotype of psoriasis with that of atopic dermatitis when both are described as 'placas descamativas', by ignoring the quality of the scale (plata, gruesa vs. fina, blanquecina) and the distribution (extensor/superficies de extensión, cuero cabelludo, uñas vs. flexural).
Both are common, chronic, pruritic plaque diseases, and stems often omit the classic buzzwords, so candidates pattern-match on 'placa crónica' alone.
What to do instead
Anchor on three discriminators: scale character, distribution, and nail involvement (pitting, onicólisis, mancha de aceite favor psoriasis). Flexural involvement without scale in an infant favors atopic dermatitis or candidiasis, not psoriasis.
Choosing topical or oral antifungal therapy for a lesion that is actually a dermatophytid, annular psoriasis, or nummular eczema, because the stem describes an annular scaling plaque and the candidate assumes 'tinea corporis' without checking the advancing border and central clearing.
Annular morphology is over-associated with tinea in training, and the KOH result is often not given, so candidates fill the gap with the most familiar diagnosis.
What to do instead
For any annular lesion, state explicitly whether there is an active scaly advancing edge with central clearing (tinea), uniform scale throughout (psoriasis/eczema), or a collarette of scale (pityriasis rosea). If the stem gives a negative KOH or failed antifungals, drop tinea.
Missing a drug eruption as the cause of a morbilliform or urticarial eruption in a child or adult and instead labeling it 'viral exanthem' or 'urticaria idiopática', without reviewing the medication timeline in the stem.
Exanthems are taught as pediatric viral illnesses, and candidates under-weight the chronology of a new drug started 7–14 days earlier, which the stem usually provides.
What to do instead
For every generalized eruption, build a medication timeline first: drug start date, eruption onset, eosinophilia or systemic signs. If a new drug precedes the rash by 1–3 weeks, name drug eruption as the leading diagnosis and specify the culprit class.
Under-staging or under-referring melanoma because the candidate focuses on Breslow thickness alone while ignoring ulceration, mitotic rate, and sentinel node status when the stem provides them.
Thickness is the most memorized prognostic factor, so candidates stop there and miss that ulceration and mitosis upstage the lesion and change the referral urgency.
What to do instead
For every melanoma stem, extract and list: Breslow, ulceration, mitoses/mm², margins, and nodal status. Then assign stage and management; if any of these is missing, state that staging is incomplete rather than guessing a stage.
Attributing nail changes to onicomicosis by default when the stem describes pitting, onicólisis with oil spots, traquioniquia, or longitudinal melanonychia, without considering psoriasis, lichen planus, or melanoma of the nail unit.
Onychomycosis is the most common nail disease, so candidates apply base rates instead of lesion-specific features, and nail melanoma is systematically under-recognized.
What to do instead
For each nail finding, ask: is the change in the matrix (pitting, traquioniquia, melanonychia) or the bed (onicólisis, oil spot, subungual hyperkeratosis)? Matrix changes point away from fungus. Any longitudinal band with Hutchinson sign or irregular pigmentation requires biopsy, not antifungals.
Recommending laser or energy-based treatment for a pigmented lesion or a condition where the stem implies diagnostic uncertainty, instead of first establishing a diagnosis and excluding malignancy.
Aesthetic questions reward knowing device indications, and candidates jump to the device without applying the safety step of excluding melanoma or active infection before treating.
What to do instead
Precede any aesthetic recommendation with a one-line safety check: diagnosis confirmed, malignancy excluded, no active infection, realistic expectation stated. If the stem leaves the diagnosis open, the correct answer is diagnosis first, treatment second.
Diagnosing an occupational or contact dermatitis without identifying the exposure pattern, and failing to recommend patch testing when the stem describes a chronic hand or facial dermatitis that relapses after holidays or worsens at work.
Candidates treat contact dermatitis as a generic eczema and skip the exposure history and the confirmatory test, which is the actual learning objective of these questions.
What to do instead
For any chronic localized dermatitis, state the distribution pattern (hands, face, eyelids, air-exposed sites) and the temporal relationship to work or a product. If pattern and chronology fit, name allergic contact dermatitis and select epicutaneous patch testing as the next step.
Missing the cutaneous marker of internal disease because the candidate treats the skin finding as an isolated dermatosis, ignoring systemic clues in the stem such as weight loss, myalgias, fever, or new-onset diabetes.
Dermatology questions are read as skin-only vignettes, so systemic red flags in the stem are skimmed past and the unifying diagnosis is never considered.
What to do instead
After naming the skin diagnosis, scan the stem once more for systemic symptoms and ask whether a paraneoplastic, endocrine, or rheumatologic association exists (e.g., acanthosis nigricans with malignancy, dermatomyositis with myositis or malignancy, erythema nodosum with sarcoidosis or IBD). If present, make the systemic workup part of the answer.